News

CellVax Therapeutics

31 de out.

CellVax Therapeutics Announces FDA Clearance of IND Application for FK-PC101, a Novel Personalized Cancer Immunotherapy

FK-PC101 is CellVax's novel personalized cancer immunotherapy intended to treat prostate cancer patients who have a high risk of...

CellVax Therapeutics

31 de out.

CellVax Submits IND Application for Individualized Cell-based Immunotherapy FK-PC101 with Support of Theragent

CellVax Therapeutics

31 de out.

Theragent to act as partner for CellVax’s Phase II cancer therapy

CellVax will examine and evaluate how FK-PC101 reduces the recurrence of prostate-specific antigens in patients. CellVax Therapeutics has...

1951 NW 7TH Ave

3rd Floor | Suite 130
Miami | FL | 33136